{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:17:53Z","timestamp":1776413873417,"version":"3.51.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The World Health Organization protocol for rabies post-exposure prophylaxis (PEP) recommends extensive wound washing, immediate vaccination, and administration of rabies immunoglobulin (RIG) in severe category III exposures. Some studies have shown that RIG can interfere with rabies vaccine immunogenicity to some extent. We investigated the interference of RIG on a next generation highly purified Vero cell rabies vaccine candidate (PVRV-NG) versus standard-of-care vaccines in a previously described hamster model. The interference of either human (h) or equine (e) RIG on the immune response elicited by PVRV-NG, Verorab<jats:sup>\u00ae<\/jats:sup> (purified Vero cell rabies vaccine, PVRV), and Imovax<jats:sup>\u00ae<\/jats:sup> Rabies (human diploid cell rabies vaccine; HDCV) was evaluated using the 4-dose Essen PEP regimen. The anti-rabies seroneutralizing titers and specific serum IgM titers were measured by fluorescent antibody virus neutralization test and enzyme-linked immunosorbent assay, respectively, for the vaccines administered with or without RIG. The RIG interference on PVRV-NG, observed transiently at Day 7, was similar to that on PVRV and tended to be lower than that on HDCV using both read-outs. In summary, the results generated in the hamster model showed that RIG induced similar or less interference on PVRV-NG than the standard-of-care vaccines.<\/jats:p>","DOI":"10.1038\/s41598-022-10281-1","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T11:06:10Z","timestamp":1650539170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Inhibitory effect of concomitantly administered rabies immunoglobulins on the immunogenicity of commercial and candidate human rabies vaccines in hamsters"],"prefix":"10.1038","volume":"12","author":[{"given":"Marie-Clotilde","family":"Bernard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Boudet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea-Clemencia","family":"Pineda-Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Guinet-Morlot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"key":"10281_CR1","unstructured":"Rabies Factsheet, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/rabies (2021)."},{"key":"10281_CR2","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1016\/j.vaccine.2018.06.061","volume":"36","author":"World Health, O","year":"2018","unstructured":"World Health, O. Rabies vaccines: WHO position paper, April 2018\u2014recommendations. Vaccine 36, 5500\u20135503. https:\/\/doi.org\/10.1016\/j.vaccine.2018.06.061 (2018).","journal-title":"Vaccine"},{"key":"10281_CR3","doi-asserted-by":"publisher","first-page":"e0003709","DOI":"10.1371\/journal.pntd.0003709","volume":"9","author":"K Hampson","year":"2015","unstructured":"Hampson, K. et al. Estimating the global burden of endemic canine rabies. PLoS Negl. Trop. Dis. 9, e0003709. https:\/\/doi.org\/10.1371\/journal.pntd.0003709 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10281_CR4","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/j.vaccine.2013.02.058","volume":"31","author":"S Pichon","year":"2013","unstructured":"Pichon, S. et al. A serum-free, purified vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab for pre-exposure use in healthy adults: Results from a randomized controlled phase-II trial. Vaccine 31, 2295\u20132301. https:\/\/doi.org\/10.1016\/j.vaccine.2013.02.058 (2013).","journal-title":"Vaccine"},{"key":"10281_CR5","doi-asserted-by":"publisher","first-page":"5940","DOI":"10.1016\/j.vaccine.2013.10.043","volume":"31","author":"R Li","year":"2013","unstructured":"Li, R. et al. A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab(R) when administered according to a post-exposure regimen in healthy children and adults in China. Vaccine 31, 5940\u20135947. https:\/\/doi.org\/10.1016\/j.vaccine.2013.10.043 (2013).","journal-title":"Vaccine"},{"key":"10281_CR6","unstructured":"The immunological basis for immunization series: module 17: rabies vaccines. http:\/\/www.who.int\/immunization\/documents\/policies\/WHO_IVB_ISBN9789241513371\/en (World Health Organization, 2017)."},{"key":"10281_CR7","unstructured":"WHO. Rabies Working Group Report, SAGE meeting October 2017, http:\/\/www.who.int\/immunization\/sage\/meetings\/2017\/october\/1_Background_paper_WG_RABIES_final.pdf?ua=1 (2017)."},{"key":"10281_CR8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/cid\/cix791","volume":"66","author":"NJ Gogtay","year":"2018","unstructured":"Gogtay, N. J. et al. Comparison of a novel human rabies monoclonal antibody to human rabies immunoglobulin for postexposure prophylaxis: A phase 2\/3, randomized, single-blind, noninferiority, controlled study. Clin. Infect. Dis. 66, 387\u2013395. https:\/\/doi.org\/10.1093\/cid\/cix791 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"10281_CR9","first-page":"491","volume":"76","author":"J Lang","year":"1998","unstructured":"Lang, J., Simanjuntak, G. H., Soerjosembodo, S. & Koesharyono, C. Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: A field trial in Indonesia. MAS054 Clinical Investigator Group. Bull. World Health Organ. 76, 491\u2013495 (1998).","journal-title":"Bull. World Health Organ."},{"key":"10281_CR10","first-page":"7","volume":"52","author":"EP Salva","year":"2014","unstructured":"Salva, E. P., Dimaano, E. M., Villarama, J. B. R. & Suquila, J. T. An evaluation of the safety and potency of equine rabies immunoglobulin through measurement of suppression on vaccine-induced antibody production among healthy volunteers. Philippine J. Intern. Med. 52, 7 (2014).","journal-title":"Philippine J. Intern. Med."},{"key":"10281_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/14760584.2018.1473765","volume":"17","author":"S Preiss","year":"2018","unstructured":"Preiss, S. et al. Post-exposure prophylaxis (PEP) for rabies with purified chick embryo cell vaccine: A systematic literature review and meta-analysis. Expert Rev. Vaccines 17, 525\u2013545. https:\/\/doi.org\/10.1080\/14760584.2018.1473765 (2018).","journal-title":"Expert Rev. Vaccines"},{"issue":"2","key":"10281_CR12","first-page":"1009","volume":"1","author":"R Audran","year":"2016","unstructured":"Audran, R. et al. Poor immune response to rabies post-exposure prophylaxis: An attempt to understand the underlying mechanisms. JSM Trop. Med. Res. 1(2), 1009 (2016).","journal-title":"JSM Trop. Med. Res."},{"key":"10281_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ijid.2005.02.007","volume":"10","author":"N Tulek","year":"2006","unstructured":"Tulek, N., Senocak, H., Yetkin, A., Un, H. & Aylan, O. Antibody response achieved by different rabies prophylaxis methods. Int. J. Infect. Dis. 10, 87\u201388. https:\/\/doi.org\/10.1016\/j.ijid.2005.02.007 (2006).","journal-title":"Int. J. Infect. Dis."},{"key":"10281_CR14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1080\/21645515.2019.1656967","volume":"16","author":"MA Matson","year":"2020","unstructured":"Matson, M. A. et al. Safety and efficacy results of simulated post-exposure prophylaxis with human immune globulin (HRIG; KEDRAB) co-administered with active vaccine in healthy subjects: A comparative phase 2\/3 trial. Hum. Vaccin. Immunother. 16, 452\u2013459. https:\/\/doi.org\/10.1080\/21645515.2019.1656967 (2020).","journal-title":"Hum. Vaccin. Immunother."},{"key":"10281_CR15","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1080\/21645515.2020.1854000","volume":"17","author":"N Hobart-Porter","year":"2021","unstructured":"Hobart-Porter, N. et al. Safety and efficacy of rabies immunoglobulin in pediatric patients with suspected exposure. Hum. Vaccin. Immunother. 17, 2090\u20132096. https:\/\/doi.org\/10.1080\/21645515.2020.1854000 (2021).","journal-title":"Hum. Vaccin. Immunother."},{"key":"10281_CR16","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1080\/21645515.2017.1307483","volume":"13","author":"G Sampath","year":"2017","unstructured":"Sampath, G. et al. Comparison of the immunogenicity and safety of the purified chick embryo cell rabies vaccine manufactured in India and Germany: A randomized, single blind, multicentre, phase IV clinical study. Hum. Vaccin. Immunother. 13, 1531\u20131538. https:\/\/doi.org\/10.1080\/21645515.2017.1307483 (2017).","journal-title":"Hum. Vaccin. Immunother."},{"key":"10281_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.15252\/emmm.201505986","volume":"8","author":"P De Benedictis","year":"2016","unstructured":"De Benedictis, P. et al. Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis. EMBO Mol. Med. 8, 407\u2013421. https:\/\/doi.org\/10.15252\/emmm.201505986 (2016).","journal-title":"EMBO Mol. Med."},{"key":"10281_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0022-1759(97)00212-3","volume":"212","author":"F Cliquet","year":"1998","unstructured":"Cliquet, F., Aubert, M. & Sagne, L. Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J. Immunol. Methods 212, 79\u201387 (1998).","journal-title":"J. Immunol. Methods"},{"key":"10281_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jviromet.2013.10.021","volume":"195","author":"M Wasniewski","year":"2014","unstructured":"Wasniewski, M. et al. Evaluation of a rabies ELISA as an alternative method to seroneutralisation tests in the context of international trade of domestic carnivores. J. Virol. Methods 195, 211\u2013220. https:\/\/doi.org\/10.1016\/j.jviromet.2013.10.021 (2014).","journal-title":"J. Virol. Methods"},{"key":"10281_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/0264-410x(88)90225-3","volume":"6","author":"I Vodopija","year":"1988","unstructured":"Vodopija, I. et al. Interaction of rabies vaccine with human rabies immunoglobulin and reliability of a 2-1-1 schedule application for postexposure treatment. Vaccine 6, 283\u2013286. https:\/\/doi.org\/10.1016\/0264-410x(88)90225-3 (1988).","journal-title":"Vaccine"},{"key":"10281_CR21","first-page":"407","volume":"39","author":"BG Archer","year":"1968","unstructured":"Archer, B. G. & Dierks, R. E. Effects of homologous or heterologous antiserum on neutralizing-antibody response to rabies vaccine. Bull World Health Organ. 39, 407\u2013417 (1968).","journal-title":"Bull World Health Organ."},{"key":"10281_CR22","doi-asserted-by":"publisher","first-page":"7141","DOI":"10.1016\/j.vaccine.2009.09.029","volume":"27","author":"CE Rupprecht","year":"2009","unstructured":"Rupprecht, C. E. et al. Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals. Vaccine 27, 7141\u20137148. https:\/\/doi.org\/10.1016\/j.vaccine.2009.09.029 (2009).","journal-title":"Vaccine"},{"key":"10281_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1006\/biol.1997.0117","volume":"26","author":"J Lang","year":"1998","unstructured":"Lang, J. et al. Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies. Biologicals 26, 7\u201315. https:\/\/doi.org\/10.1006\/biol.1997.0117 (1998).","journal-title":"Biologicals"},{"key":"10281_CR24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/s0092-1157(82)80013-9","volume":"10","author":"CG Helmick","year":"1982","unstructured":"Helmick, C. G., Johnstone, C., Sumner, J., Winkler, W. G. & Fager, S. A clinical study of Merieux human rabies immune globulin. J. Biol. Stand. 10, 357\u2013367. https:\/\/doi.org\/10.1016\/s0092-1157(82)80013-9 (1982).","journal-title":"J. Biol. Stand."},{"key":"10281_CR25","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/0264-410x(92)90510-q","volume":"10","author":"CL Schumacher","year":"1992","unstructured":"Schumacher, C. L., Ertl, H. C., Koprowski, H. & Dietzschold, B. Inhibition of immune responses against rabies virus by monoclonal antibodies directed against rabies virus antigens. Vaccine 10, 754\u2013760. https:\/\/doi.org\/10.1016\/0264-410x(92)90510-q (1992).","journal-title":"Vaccine"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10281-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10281-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10281-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T02:13:30Z","timestamp":1669342410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10281-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10281"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-10281-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,21]]},"assertion":[{"value":"3 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MCB was an employee of Sanofi  at the time of submission of the manuscript. FB, ACPP, and FGM are currently employees of Sanofi. ACPP, MCB, and FB may hold shares in the company.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6570"}}